Biologics for chronic rhinosinusitis with nasal polyps: Economics and ethics. Issue 11 (11th July 2021)

• Record Type: Journal Article
• Authors: Roland, Lauren T.; Regenberg, Alan; Luong, Amber U.; Wise, Sarah K.; Toskala, Elina; Lam, Kent K.; Levy, Joshua M.; Franzese, Christine B.; Smith, Kristine; Kim, Jean
• Is Part Of: International forum of allergy & rhinology. Volume 11:Issue 11(2021)
• Page Start: 1524
• Page End: 1528
• Publication Date: 2021-07-11
• Subjects: chronic rhinosinusitis -- medical therapy of chronic rhinosinusitis -- rhinosinusitis; 617.51005
• DOI: 10.1002/alr.22864
• Languages: English
• ISSNs: 2042-6976

Abstract

Summary: Biologics have recently been approved for use in chronic rhinosinusitis with nasal polyps patients. While effective in controlling disease on subjective and objective short‐term outcome measures, limited data suggest that biologics have the potential to be used long term. The current wholesale acquisition costs for biologics are quite high. Widespread, prolonged use of these medications may create a large burden to our healthcare system. Cost‐effectiveness analyses, particularly for specific patient cohorts, are needed to determine appropriate use of these medications. The ethics of patient preference of various treatment options, counseling regarding side effect profiles, and healthcare economics also need to be addressed.